Market Place
Sourcing Support
Apellis Presents Phase 3 VALIANT Study At ASN Kidney Week
16 Oct 2024 //
GLOBENEWSWIRE
Apellis Receives Negative CHMP Opinion for Pegcetacoplan
20 Sep 2024 //
GLOBENEWSWIRE
Sobi And Apellis Report Positive Results From Pegcetacoplan Study
09 Aug 2024 //
PR NEWSWIRE
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Apellis To Present Five Oral Abstracts At ASRS Annual Meeting
09 Jul 2024 //
GLOBENEWSWIRE
EU`s drug regulator again rejects Apellis` eye med and PTC`s Translarna
02 Jul 2024 //
FIERCE PHARMA
Apellis Seeks Re-Examination Following Negative CHMP Opinion For Pegcetacoplan
28 Jun 2024 //
GLOBENEWSWIRE
SYFOVRE Preserved Vision In Geographic Atrophy Extension Study
10 Jun 2024 //
GLOBENEWSWIRE
Pegcetacoplan Noble Phase 2 Positive: Era Late-Breaker Presentation Featured
24 May 2024 //
PR NEWSWIRE
Pegcetacoplan 1-Year C3G Ic-Mpgn: Positive Post-Transplant Data At Era
24 May 2024 //
GLOBENEWSWIRE
Apellis takes it slow with first Syfovre DTC campaign
23 May 2024 //
FIERCE PHARMA
Sobi’s Aspaveli obtains indication extension approval in Europe
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Aspaveli Approved In Europe For Treatment Naïve PNH Patients
08 May 2024 //
PR NEWSWIRE
Apellis: Pegcetacoplan MAA Review Reset by EMA
26 Apr 2024 //
GLOBENEWSWIRE
Apellis Pharma Gets Negative CHMP Opinion for Intravitreal Pegcetacoplan
27 Jan 2024 //
PRESS RELEASE
EMPAVELI Provided Long-Term Control of PNH in New Data Presented
11 Dec 2023 //
GLOBENEWSWIRE
SYFOVRE Continued to ShowTreatment Effects Over 3 Years in Patients with GA
04 Nov 2023 //
GLOBENEWSWIRE
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE forGA
20 Oct 2023 //
GLOBENEWSWIRE
Empaveli is the first treatment for PNH that binds to the complement protein C3.
17 Oct 2023 //
BUSINESSWIRE
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan
17 Oct 2023 //
GLOBENEWSWIRE
Apellis Receives Permanent J-Code (J2781) for SYFOVRE, Effective October 1, 2023
25 Sep 2023 //
GLOBENEWSWIRE
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE & EMPAVELI
29 Aug 2023 //
GLOBENEWSWIRE
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE
22 Aug 2023 //
GLOBENEWSWIRE
Apellis bolsters case for Syfovre amid second-quarter earnings
31 Jul 2023 //
FIERCE PHARMA
SYFOVRE Continued to show Increasing Treatment Effects Over 30 Months in GA
30 Jul 2023 //
PRESS RELEASE
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE
29 Jul 2023 //
PRESS RELEASE
Experts report eye inflammation cases linked to Apellis` Syfovre
18 Jul 2023 //
FIERCE PHARMA
Apellis scraps pegcetacoplan development in ALS after trial flop
26 May 2023 //
FIERCE PHARMA
Apellis reports strong start for new vision loss drug
06 May 2023 //
BIOPHARMADIVE
Apellis Announces Validation of 4Marketing Applications for Pegcetacoplanrophy
21 Apr 2023 //
GLOBENEWSWIRE
University Retina Participate in Apellis’ Groundbreaking Trials for SYFOVRE
01 Mar 2023 //
BUSINESSWIRE
FDA approves first treatment for geographic atrophy
21 Feb 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Apellis wins FDA approval for first geographic atrophy drug
18 Feb 2023 //
FIERCE PHARMA
Apellis Submits Marketing Authorization Application to EMA for Pegcetacoplan
16 Dec 2022 //
GLOBENEWSWIRE
Health Canada grants approval for Sobi’s PNH therapy
12 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Sobi Receives Approval from Health Canada for Empaveli (pegcetacoplan)
09 Dec 2022 //
GLOBENEWSWIRE
Apellis` closely watched eye drug gets new FDA goal date
19 Nov 2022 //
FIERCEPHARMA
Apellis Announces Plans to Submit 24-Month Ph3 Data to the FDA for Pegcetacoplan
04 Nov 2022 //
PRESS RELEASE
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacyof EMPAVELI
03 Nov 2022 //
PRESS RELEASE
Apellis Announces 24-Month Ph3 Post Hoc Results Showing Treatment Pegcetacoplan
30 Sep 2022 //
GLOBENEWSWIRE
Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned
07 Sep 2022 //
ENDPTS
Apellis Announces Results Showing Increased Effects with Pegcetacoplan in PIII
24 Aug 2022 //
GLOBENEWSWIRE
DRI Healthcare Trust Announces Acquisition of a Royalty Interest
21 Jul 2022 //
NEWSWIRE
Avadel Pharma Announces Tentative Approval of LUMRYZ ER oral suspension
19 Jul 2022 //
GLOBENEWSWIRE
Apellis Submits NDA to FDA for Pegcetacoplan for Geographic Atrophy
01 Jun 2022 //
GLOBENEWSWIRE
Sobi`s Biologic Aspaveli (Pegcetacoplan) Receives Approval in Europe
21 Feb 2022 //
EMA
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated
13 Dec 2021 //
GLOBENEWSWIRE
NICE recommends Aspaveli ahead of MHRA decision
10 Dec 2021 //
THEPHARMALETTER
Apellis eye med speeds toward first-half 2022 submission
16 Nov 2021 //
FIERCEPHARMA
Apellis to Present New Data Reinforcing EMPAVELI Efficacy and Safety
04 Nov 2021 //
GLOBENEWSWIRE
Apellis` Empaveli could reap $4B in race against Alexion drugs
20 Aug 2021 //
FIERCEPHARMA
Pegcetacoplan Maintains a Durable Response in Patients with PNH Through Week 48
14 Jun 2021 //
PRNEWSWIRE
Pegcetacoplan Maintains Response in Paroxysmal Nocturnal Hemoglobinuria
12 Jun 2021 //
PRNEWSWIRE
Apellis` Soliris rival gets a date at the FDA for a rare blood disorder
17 Nov 2020 //
ENDPTS
Apellis Completes Enrollment in Ph3 Study of Pegcetacoplan-Naïve Patients
02 Jul 2020 //
GLOBENEWSWIRE
